Otros idiomas DURECT Corporation

Acciones

DRRX

US2666055007

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 21/06/2024			Varia. Cinco días.	Varia. 1 de enero.
1,51 ^USD	+1,34 %		-8,48 %	+155,93 %

21/05	DURECT Corporation recibe la designación de terapia innovadora de la FDA para el larsucosterol en la hepatitis asociada al alcohol	CI
21/05	Actualización del sector: Los valores del sector sanitario suben el martes por la tarde	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis	21/05
Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon	21/05
Durect Gets FDA Breakthrough Therapy Designation for Alcohol-Related Hepatitis Treatment	21/05
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis	21/05
Durect Far From Earnings Story But FDA Commentary Shows Path Forward, Oppenheimer Says	14/05
Durect: Q1 Earnings Snapshot	13/05
DURECT Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Earnings Flash (DRRX) DURECT CORPORATION Reports Q1 Revenue $1.8M, vs. Street Est of $2.7M	13/05
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update	13/05
DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update	07/05
DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis	30/04
Durect: Q4 Earnings Snapshot	27/03
DURECT Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Earnings Flash (DRRX) DURECT CORPORATION Posts Q4 Revenue $2.7M, vs. Street Est of $2.7M	27/03
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	27/03
DURECT Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/03
North American Morning Briefing : Stocks Edge -2-	27/03
DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update	20/03
North American Morning Briefing : Stock Futures -2-	19/03
DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada	04/03

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas DURECT Corporation

Acciones

DRRX

US2666055007

Otros idiomas

Filtros